ALSO NOTED: U.K. calls for halt to HIV study; Cadence to raise $49.3M; and much more...

> The U.K.'s Medical Research Council has advised Indevus Pharmaceuticals to close the high-dose arm of it's Phase III HIV study. Release

> Cadence Pharmaceuticals is raising $49.3 million in a registered direct common stock offering. Release

> The heparin pile-on has begun--but this time, the FDA is at the bottom, not the drugmaker. Report

> Well, we didn't have to watch Alex Gorsky for long. According to the Wall Street Journal, when Novartis said that the U.S. pharma CEO was leaving, they left out the part about his returning to alma mater Johnson & Johnson. Report

> The FDA has approved a label change adding depression as a possible side effect of the cholesterol meds Vytorin and Zetia. Report

> Sanofi Pasteur has submitted the first vaccine delivered by an intradermal microinjection system for European approval. Report

> Despite spending a dramatically higher amount than before on treatments for spinal pain, Americans aren't getting great results, according to a new study. Report

> FierceHealthcare asks: Would a new agency curb pharma marketing misdeeds? Editorial

And Finally... Natural purple pigments found in fruits, vegetables and berries may help prevent obesity. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.